Sorafenib and lithium chloride combination treatment shows promising synergistic effects in human glioblastoma multiforme cells in vitro but midkine is not implicated

References

• Nakazato Y. WHO classification of tumours of the central nervous system, 4th edn., Vol. 36, No Shinkei Geka; 2008. p. 473–91.
   Google Scholar
• Schneider T, Mawrin C, Scherlach C, Skalej M, Firsching R. Gliomas in adults. Dtsch Arztebl Int. 2010;107:799–807.
   PubMedGoogle Scholar
• Krakstad C, Chekenya M. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer. 2010;9:135.
   PubMed Web of Science ®Google Scholar
• Martínez R. Beyond genetics in glioma pathways: the ever-increasing crosstalk between epigenomic and genomic events. J Signal Transduct. 2012;2012:9.
   Google Scholar
• Binda E, Visioli A, Reynolds B, Vescovi AL. Heterogeneity of cancer-initiating cells within glioblastoma. Front Biosci (Schol Ed). 2012;4:1235–48.
   PubMedGoogle Scholar
• Bai RY, Staedtke V, Riggins GJ. Molecular targeting of glioblastoma: drug discovery and therapies. Trends Mol Med. 2011;17:301–12.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. Expert Rev Neurother. 2010;10:1537–44.
   PubMed Web of Science ®Google Scholar
• Iyer R, Fetterly G, Lugade A, Thanavala Y. Sorafenib. A clinical and pharmacologic review. Expert Opin Pharmacother. 2010;11:1943–55.
   PubMed Web of Science ®Google Scholar
• Arranz JA, Climent MA, González-Larriba JL, León L, Maroto JP. Sorafenib in renal cell carcinoma. Crit Rev Oncol Hematol. 2011;80:314–22.
   PubMed Web of Science ®Google Scholar
• Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology. 2011;140:1410–26.
   PubMed Web of Science ®Google Scholar
• Grignani G, Palmerini E, Dileo P, Asaftei SD, D'Ambrosio L, Pignochino Y, . A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2012;23:508–16.
   PubMed Web of Science ®Google Scholar
• Pasqualetti G, Ricciardi S, Mey V, Del Tacca M, Danesi R. Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines. Lung Cancer. 2011;74:197–205.
   PubMed Web of Science ®Google Scholar
• Siegelin MD, Raskett CM, Gilbert CA, Ross AH, Altieri DC. Sorafenib exerts anti-glioma activity in vitro and in vivo. Neurosci Lett. 2010;478:165–70.
   PubMed Web of Science ®Google Scholar
• Gumus AB, Cam O, Malak AT. Relationships between psychosocial adjustment and hopelessness in women with breast cancer. Asian Pac J Cancer Prev. 2011;12:433–8.
   PubMedGoogle Scholar
• Neilson KA, Pollard AC, Boonzaier AM, Corry J, Castle DJ, Mead KR, . Psychological distress (depression and anxiety) in people with head and neck cancers. Med J Aust. 2010;193:S48–51.
   PubMed Web of Science ®Google Scholar
• Adler JT, Hottinger DG, Kunnimalaiyaan M, Chen H. Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors. Ann Surg Oncol. 2009;16:481–6.
   PubMed Web of Science ®Google Scholar
• Bilir A, Erguven M, Yazihan N, Aktas E, Oktem G, Sabanci A. Enhancement of vinorelbine-induced cytotoxicity and apoptosis by clomipramine and lithium chloride in human neuroblastoma cancer cell line SH-SY5Y. J Neurooncol. 2010;100:385–95.
   PubMed Web of Science ®Google Scholar
• Nowicki MO, Dmitrieva N, Stein AM, Cutter JL, Godlewski J, Saeki Y, . Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3. Neuro-Oncology. 2008;10:690–9.
   PubMed Web of Science ®Google Scholar
• Pasquali L, Busceti CL, Fulceri F, Paparelli A, Fornai F. Intracellular pathways underlying the effects of lithium. Behav Pharmacol. 2010;21:473–92.
   PubMed Web of Science ®Google Scholar
• Korur S, Huber RM, Sivasankaran B, Petrich M, Morin P Jr, Hemmings BA, . GSK-3-beta regulates differentiation and growth arrest in glioblastoma. PLoS One. 2009;4:e7443.
   PubMed Web of Science ®Google Scholar
• Dai LC. Midkine translocated to nucleoli and involved in carcinogenesis. World J Gastroenterol. 2009;15:412–6.
   PubMed Web of Science ®Google Scholar
• Mishima K, Asai A, Kadomatsu K, Ino Y, Nomura K, Narita Y, . Increased expression of midkine during the progression of human astrocytomas. Neurosci Lett. 1997;233:29–32.
   PubMed Web of Science ®Google Scholar
• Muramatsu T. Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86:410–25.
   PubMed Web of Science ®Google Scholar
• Erguven M, Bilir A, Yazihan N, Ermis E, Sabanci A, Aktas E, . Decreased therapeutic effects of noscapine combined with imatinib mesylate on human glioblastoma in vitro and the effect of midkine. Cancer Cell Int. 2011;11:18.
   PubMed Web of Science ®Google Scholar
• Erguven M, Bilir A, Yazihan N, Korkmaz S, Aktas E, Ovalioglu C, . Imatinib mesylate decreases the cytotoxic effect of roscovitine on human glioblastoma cells in vitro and the role of midkine. Oncol Lett. 2012;3:200–8.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Ervin T, Friedman E, Priego V, Murphy PB, Clark BL, . Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer. 2010;116:3663–9.
   PubMed Web of Science ®Google Scholar
• Jane EP, Premkumar DR, Pollack IF. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J Pharmacol Exp Ther. 2006;319:1070–80.
   PubMed Web of Science ®Google Scholar
• Agarwal S, Sane R, Ohlfest JR, Elmquist WF. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther. 2011;336:223–33.
   PubMed Web of Science ®Google Scholar
• Bilir A, Erguven M, Ermis E, Sencan M, Yazihan N. Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro. J Gynecol Oncol. 2011;22:225–32.
   PubMed Web of Science ®Google Scholar
• Hu R, Yan Y, Li Q, Lin Y, Jin W, Li H, . Increased drug efflux along with midkine gene high expression in childhood B-lineage acute lymphoblastic leukemia cells. Int J Hematol. 2010;92:105–10.
   PubMed Web of Science ®Google Scholar
• Brantley EC, Benveniste EN. Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res. 2008;6:675–84.
   PubMed Web of Science ®Google Scholar
• Bredel M, Scholtens DM, Yadav AK, Alvarez AA, Renfrow JJ, Chandler JP, . NFKBIA deletion in glioblastomas. N Engl J Med. 2011;364:627–37.
   PubMed Web of Science ®Google Scholar
• Chakravarti A, Chakladar A, Delaney MA, Latham DE, Loeffler JS. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res. 2002;62:4307–15.
   PubMed Web of Science ®Google Scholar
• Lo HW. EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance. Curr Mol Pharmacol. 2010;3:37–52.
   PubMedGoogle Scholar
• Edwards JP, Emens LA. The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE2 in murine macrophages. Int Immunopharmacol. 2010;10:1220–8.
   PubMed Web of Science ®Google Scholar
• Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS, . SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 2011;471:104–9.
   PubMed Web of Science ®Google Scholar
• Panka DJ, Cho DC, Atkins MB, Mier JW. GSK-3-beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. J Biol Chem. 2008;283:726–32.
   PubMed Web of Science ®Google Scholar
• Vogl UM, Berger W, Micksche M, Pirker C, Lamm W, Pichelmeyer O, . Synergistic effect of sorafenib and sunitinib with enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines. Cancer Lett. 2009;277:218–26.
   PubMed Web of Science ®Google Scholar
• Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, . Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res. 2012;18:4997–5007.
   PubMed Web of Science ®Google Scholar
• Koivisto L, Jiang G, Häkkinen L, Chan B, Larjava H. HaCaT keratinocyte migration is dependent on epidermal growth factor receptor signaling and glycogen synthase kinase-3alpha. Exp Cell Res. 2006;312:2791–805.
   PubMed Web of Science ®Google Scholar
• Wu JM, Sheng H, Saxena R, Skill NJ, Bhat-Nakshatri P, Yu M, . NF-kappa-β inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Lett. 2009;278:145–55.
   PubMed Web of Science ®Google Scholar
• Kotliarova S, Pastorino S, Kovell LC, Kotliarov Y, Song H, Zhang W, . Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappa-β, and glucose regulation. Cancer Res. 2008;68:6643–51.
   PubMed Web of Science ®Google Scholar
• Zhivotovsky B, Orrenius S. Cell death mechanisms: cross-talk and role in disease. Exp Cell Res. 2010;316:1374–83.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Ren X, Hait WN, Yang JM. Therapeutic targeting of autophagy in disease: biology and pharmacology. Pharmacol Rev. 2013;65:1162–97.
   PubMed Web of Science ®Google Scholar